← Leaderboards
Robert Giannini
Irisys, Inc.
$6,513,140
Attributed
$6,513,140
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2010–24$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,513,140 · 4
By mechanism
N02$4,784,937 · 3
N01$1,728,203 · 3
Top collaborators
No co-investigators on record.
Most similar at Irisys, Inc.
Same institution · by research overlap
- Yevgeniya Plekhov$412,500
- Miray Mousa$249,951
Others in their field
Top investigators on “Capsule”
- Alan G. Barbour · University Of California Irvine$39,660,285
- Arturo Casadevall · Johns Hopkins University$21,055,487
- Guillermo J. Tearney · Massachusetts General Hospital$18,212,298
- Suzanne N Haber · University Of Rochester$15,483,746
- Thomas R Kozel · La Biomed Res Inst/ Harbor Ucla Med Ctr$13,657,306
- Joann Elisabeth Manson · Brigham And Women'S Hospital$12,031,248
Research focus
CapsuleContractorProductionRepositoryLifeFormulationContractsSealLabelGelatinPharmacologic SubstanceDosage FormsClinical TrialsCyclic GmpOralPharmaceutical PreparationsDevelopmental Therapeutics ProgramTabletsTherapeutic AgentsToxicologyManufactured SuppliesJointsBaseMission
Grant awards (40)
SOCIETAL IS A SMALL BUSINESS CONCERN FOR DOSAGE FORM DEVELOPMENT, MANUFACTURE, AND STABILITY STUDIES OF NCGC72$565,585
N01 · FY2024 · DA · contact PI
SOCIETAL IS A SMALL BUSINESS CONCERN FOR DOSAGE FORM DEVELOPMENT, MANUFACTURE, AND STABILITY STUDIES OF NCGC72$182,902
N01 · FY2023 · DA · contact PI
NExT DTP-23-019 GMP PRODUCTION OF 40MG CAPSULES OF Z-ENDOXIFEN$140,000
N02 · FY2023 · CA · contact PI
DOSAGE FORM DEVELOPMENT, MANUFACTURE, AND STABILITY STUDIES OF AVE-1625 (DRINABANT. DRINABANT) IV BAG STUDY$79,600
N01 · FY2023 · DA · contact PI
NEXT DTP-23-017, PRODUCTION OF 0.25MG OF AZATDC AND TDCYD CAPSULES$66,182
N02 · FY2023 · CA · contact PI
NEXT DTP-22-013, PRODUCTION OF TAK-243 INJECTABLE FOR CLINICAL USE$639,151
N02 · FY2022 · CA · contact PI
PRODUCTION OF AMMONIUM TETRATHIOMOLIBDATE (ATTM) CAPSULES FOR USE IN CLINICAL TRIALS$413,130
N01 · FY2022 · CA · contact PI
NEXT DTP-22-018, GMP PRODUCTION OF 40 MG Z-ENDOXIFEN (NSC 774768) CAPSULES$189,535
N02 · FY2022 · CA · contact PI
AZA-TDC CAPSULES FOR USE IN CLINICAL TRIAL$177,135
N01 · FY2022 · CA · contact PI
PRODUCTION OF VARIOUS STRENGTH OF IPDR CAPSULES FOR CLINICAL USE;$115,290
N02 · FY2021 · CA · contact PI
PRODUCTION OF VARIOUS STRENGTH OF INJECTABLE LMP744 FOR CLINICAL USE; POP: 02/14/2020 - 02/13/2021$512,500
N02 · FY2020 · CA · contact PI
PRODUCTION OF VARIOUS STRENGTH OF IPDR CAPSULES FOR CLINICAL USE; POP: 05/08/2020 - 05/07/2021$109,800
N02 · FY2020 · CA · contact PI
THE PURPOSE OF THIS TASK ORDER IS TO PRODUCE ONE BATCH OF 10,000 ENDOXIFEN CAPSULES, 40 MG PER CAPSULE. (POP: 01/30/2020 TO 06/29/2020)$100,393
N02 · FY2020 · CA · contact PI
PRODUCTION OF VARIOUS STRENGTH OF AZA-TDC CAPSULES FOR CLINICAL USE POP: 03/16/2020 - 03/15/2021$97,467
N02 · FY2020 · CA · contact PI
Production of Triapine Injection for Clinical Use$137,972
N02 · FY2019 · CA · contact PI
Production of Aza-TdC Capsules for Clinical Use$97,042
N02 · FY2019 · CA · contact PI
manufacturing four (4) mg Aza-TdC Capsules$71,645
N02 · FY2019 · CA · contact PI
Indenos (LMP744, NSC 706744) for Injection$178,467
N02 · FY2018 · CA · contact PI
IGF::OT::IGF PRODUCTION OF 600 BOTTLES OF TETRAHYDROURIDINE POWDER$73,009
N02 · FY2018 · CA · contact PI
Task Order 27: Study the Stabilizing Effect of StabilOx System on Tetra Thiomolybdate$30,496
N02 · FY2018 · CA · contact PI
Z-Endoxifen HCl Capsules$239,627
N02 · FY2017 · CA · contact PI
IGF::OT::IGF$179,379
N02 · FY2017 · CA · contact PI
IGF::OT::IGF$82,758
N02 · FY2017 · CA · contact PI
BASE AWARD$82,758
N02 · FY2017 · CA · contact PI
IPdR Capsules, 600mg Strength$80,834
N02 · FY2017 · CA · contact PI
IGF::OT:IGF$77,283
N02 · FY2017 · CA · contact PI
Production and Evaluation of the stability of Tetrathiomolibdate Capsules (Non GMP study)$17,542
N02 · FY2017 · CA · contact PI
Conducting Assay, Purity profile, and Dissolution rate for Decitabine Capsules$8,280
N02 · FY2017 · CA · contact PI
IGF::OT::IGF SPECIAL STUDIES/ANALYSIS- CHEMICAL/BIOLOGICAL$156,438
N02 · FY2016 · CA · contact PI
IGF::OT::IGF TASK ORDER 15$84,607
N02 · FY2016 · CA · contact PI
IGF::OT::IGF SPECIAL STUDIES/ANALYSIS- CHEMICAL/BIOLOGICAL$71,350
N02 · FY2016 · CA · contact PI
IGF::OT::IGF TASK ORDER 13$70,868
N02 · FY2016 · CA · contact PI
IGF::OT::IGF PRODUCTION OF 650 BOTTLES OF TETRAHYDROURIDINE POWDER, HHSN261201200009I/HHSN26100009, DTP-16-003, DEVELOPMENT AND MANUFACTURE OF ORAL AND TOPICAL DOSAGE FORMS, PRBPERIOD OF PERFORMANCE$66,927
N02 · FY2016 · CA · contact PI
IGF::OT::IGF 4-THIO-2-DEOXYCYTIDINE, MANUFACTURE A BATCH OF 10 MG STRENGTH CAPSULES UNDER GMP$60,424
N02 · FY2016 · CA · contact PI
TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS$144,980
N02 · FY2015 · CA · contact PI
TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS$309,851
N01 · FY2014 · CA · contact PI
TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS$283,206
N02 · FY2013 · CA · contact PI
TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS$130,000
N02 · FY2012 · CA · contact PI
TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS$62,000
N02 · FY2011 · CA · contact PI
TAS::75 0849::TAS DEVELOPMENT AND MANUFACTURE OF ORAL AND TOOPICAL DOSAGE FORMS$326,727
N02 · FY2010 · CA · contact PI